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A B S T R A C T
Objective: Very few studies have been conducted in this part of world to see relation between maternal
serum homocysteine levels and congenital heart disease in their offsprings. With this perspective in
mind, this study was carried out.
Methods: Fifty women were enrolled in this study. Thirty of these had delivered neonates who were
diagnosed to have congenital heart diseases. These were treated as cases. Twenty of these women had
delivered neonates who did not have any congenital heart diseases and were treated as controls. For
estimating the levels of plasma homocysteine, fasting blood samples were taken from the women in both
groups.
Results: Out of 30 cases, 14 (46.6%) had a tHcy level more than 15 mmol/l and all these women had
delivered babies who were found to have congenital heart diseases. Out of controls, only 3 (15%) had a
tHcy level more than 15 mmol/l. In babies with ventricular septal defects, the mean maternal plasma
tHcy level was 13.30 mmol/l. In babies with Tetralogy of Fallot, the mean maternal plasma tHcy level was
40.07 mmol/l. In babies with Transposition of Great Vessels, the mean maternal plasma tHcy level was
40.93 mmol/l. In babies with Tricuspid atresia, the mean maternal plasma tHcy level was 24.89 mmol/l.
Conclusions: Increased levels of maternal serum homocysteine are associated with increased risk of
occurrence of congenital heart defects in their offsprings, suggesting that maternal hyperhomocys-
teinemia is an independent risk factor for congenital heart defects.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Congenital heart diseases are mainly the result of incomplete
development of heart during the ﬁrst six weeks of pregnancy.
Although in recent years, several medical and surgical advances
have improved the survival rates of infants with congenital heart
diseases,1–3 not all affected infants can be successfully treated
surgically, and the treatment itself has considerable social,
economic and personal costs.3 Moreover, the long term prognosis
of infants who have been surgically treated has not been clearly
determined.4 These concerns highlight the importance and
potential impact of primary prevention of congenital heart defects.
Studies in the recent past have shown that increased levels of
maternal serum homocysteine are associated with increased risk
of occurrence of congenital heart defects in their offsprings,* Corresponding author.
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creativecommons.org/licenses/by-nc-nd/4.0/).suggesting that maternal hyperhomocysteinemia is an indepen-
dent risk factor for congenital heart defects,5–8 by interfering with
the development of conotruncal septum of heart.
Very few studies have been conducted in this part of the world
to see relation between maternal serum homocysteine levels and
congenital heart disease in their offsprings. With this perspective
in mind, this study was carried out.
2. Methods
This prospective study was carried out in a tertiary care hospital
in north India over a period of one year. The study cohort was
selected from the obstetric department of the hospital. Fifty
women were enrolled in this study. Thirty of these had delivered
neonates who were diagnosed to have congenital heart diseases
(except patent ductus arteriosus, atrial septal defects and
syndromal associations). These 30 women were treated as cases.
Twenty of these women had delivered neonates who did not have
any congenital heart diseases. These 20 women were treated asmocysteinemia and congenital heart defects: A prospective case
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Table 3
The plasma homocysteine levels (tHcy) levels in cases and controls.
Range of plasma
tHcy in mmol/l
Mean plasma
tHcy in mmol/l
S.D.
Cases 5.5–46.88 24.36 16.6
Controls 7.66–45.6 14.16 13.14
p = 0.013.
Table 4
Risk of CHD in association with maternal plasma homocystiene levels.
tHcy <15 mmol/l tHcy >15 mmol/l
Number Percent Number Percent
Cases 16 48.49 14 82.35
Controls 17 51.51 3 17.65
Total 33 100 17 100
x2 = 5.362, p = 0.02.
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consumption of any multivitamin preparation in three months
preceding delivery. Women from rural as well as urban back-
grounds were included in the study.
The criteria for diagnosis of congenital heart diseases in
neonates born to these women was based on detailed history
and a thorough clinical examination, and conﬁrmed by chest
radiography, electrocardiography and echocardiography.
For estimating the levels of plasma homocysteine, fasting blood
samples were taken from the women in both groups nine to ﬁfteen
months after the index delivery. The blood samples were
immediately centrifuged and plasma was separated and stored
in a deep freezer. All the plasma samples were analyzed in a single
sitting using ELISA method, and computed results were obtained in
mmol/l. Statistical analysis was done using GraphPad Instat
statistical software.
Ethical clearance was obtained from Institutional Ethical
Committee (IEC) and written informed consent was taken from
all participants.
3. Results
The study cohort consisted of 50 participants (Table 1). Out of
these, 30 (60%) were cases who had delivered babies with congenital
heart defects and 20 (40%) were controls who had delivered normal
babies. 28 participants (56%) were from rural background and 22
(44%) were from urban background. 17 (56.67%) of the cases were
from rural background and 13 (43.3%) were from urban background.
Out of the 20 controls, 11 (55%) were from rural background and 9
(45%) were from urban background.
The distribution of congenital heart defects in the babies is
shown in Table 2.
The plasma homocysteine levels (tHcy) levels in cases and
controls are shown in Table 3.
Out of 30 cases, 14 (46.6%) had a tHcy level more than 15 mmol/l
and all these women had delivered babies who were found to have
congenital heart diseases. Out of controls, only 3 (15%) had a tHcy
level more than 15 mmol/l.
Out of 30 cases, 16 (53.33%) had a tHcy level less than 15 mmol/l
and out of 20 controls, 17 (85%) had a tHcy level less than 15 mmol/l.
These differences were statistically signiﬁcant, with a p value of
0.02 and x2 of 5.362 (Table 4).
Among the 30 babies with congenital heart diseases, the
maternal plasma tHcy levels were compared in various defects. In
babies with ventricular septal defects, the maternal plasma tHcyTable 1
Baseline characters of cases and controls.
Character Cases Controls
Median maternal age 32.2 years 32.6 years
Residential background 17 rural, 13 urban 11 rural, 9 urban
Mode of delivery 12 LSCS, 18 NVD 12 NVD, 8 LSCS
Mean maternal hemoglobin 11.1 g/dl 11 g/dl
Maternal cigarette/alcohol use Nil Nil
LSCS – lower segment caesarian section; NVD – normal vaginal delivery.
Table 2
Distribution of congenital heart defects in the babies.
Type of cardiac defect Number of patients Percentage
Ventricular septal defect 19 63.34
Tetralogy of Fallot 6 20
Transposition of Great Vessels 3 10
Tricuspid atresia 2 6.66
Total 30 100
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13.30 mmol/l. in babies with Tetralogy of Fallot, the maternal
plasma tHcy level was in range of 17.5–46.88 mmol/l, with a mean
level of 40.07 mmol/l. In babies with Transposition of Great Vessels,
the maternal plasma tHcy level was in range of 29.28–46.83 mmol/
l, with a mean level of 40.93 mmol/l in babies with Tricuspid
atresia, the maternal plasma tHcy level was in range of 8.45–
41.25 mmol/l, with a mean level of 24.89 mmol/l.
4. Discussion
Congenital heart defects are the leading cause of deaths due to
congenital anomalies.9,10 Congenital heart defects have now
surpassed anencephaly and spina biﬁda as a leading cause of
infant deaths. Although the diagnostic and treatment modalities
for congenital heart diseases have improved vastly, the goal of
medical and public health personnel should be to ﬁnd effective
means for primary prevention of congenital heart defects.
In this study, ventricular septal defects were the most common
congenital cardiac defects seen in the newborn babies. This is
similar to the incidence of ventricular septal defects in the general
population as reported by Goldmuntz.11
We observed that 46.67% of the study group subjects had a
fasting hyper-homocysteinemia, as compared to only 15% in the
control group. This difference was statistically signiﬁcant
(p = 0.021). Also, the mean fasting total plasma homocysteine
levels in the study group were higher (24.36 mmol/l) than that in
the control group (14.16 mmol/l). This difference was also
statistically signiﬁcant (p = 0.013). Livia et al.5 also found similar
results in their study. They found that mean fasting plasma
homocysteine levels in 27 women who had given birth to babies
with congenital heart diseases was higher than in those who gave
birth to normal babies. They observed fasting hyper homocystei-
nemia in 46.2% of study group subjects as compared to 14.3%
controls. They also carried out median methionine levels after
loading plasma homocysteine and found that these concentrations
were not higher in the study group.
In a recent study by Verkleij-Hagoort et al.,12 it was seen that a
high maternal fasting tHcy level was associated with a threefold
higher risk of a child with congenital heart defect in a
concentration dependant manner. Just like our results as depicted
in Table 3, they saw that the risk for CHD increased with increasing
maternal tHcy concentrations.
In another recent study by Charlotte et al.,13 it was seen that just
like our results, case subjects had higher mean concentrations of
homocysteine (p = 0.001) than did control subjects.mocysteinemia and congenital heart defects: A prospective case
doi.org/10.1016/j.ihj.2016.07.014
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homocysteine levels in mothers who delivered babies with
Tetralogy of Fallot and Transposition of Great Vessels were higher
(40.93 mmol/l and 40.17 mmol/l respectively). The mean total
plasma homocysteine levels in mothers who delivered babies with
ventricular septal defects and Tricuspid atresia were comparative-
ly lower (13.3 mmol/l and 24.89 mmol/l respectively). This
suggests a possibly stronger association of occurrence of Transpo-
sition of Great Vessels and Tetralogy of Fallot with maternal
hyperhomocysteinemia.
Since the neural crest cells contribute to the outﬂow portion of
the septum of heart,14 it can be assumed that the altered
homocysteine metabolism, as reported in neural tube defects,
may play the same role in congenital heart defects. No increase in
incidence of both these defects in newborns has been reported
probably because these fetuses are aborted in early pregnancy.
In a number of studies,15,16 the role of periconceptional
multivitamins containing folic acid and the reduced risk of
occurrence of congenital heart diseases in offsprings has been
studied. Normalization of plasma homocysteine levels has been
cited as one of the possible mechanisms of folic acid in these cases.6
Thus, we conclude from this study in Asian population that
increased levels of maternal serum homocysteine are associated
with increased risk of occurrence of congenital heart defects in
their offsprings, suggesting that maternal hyperhomocysteinemia
is an independent risk factor for congenital heart defects. It would
be prudent to recommend folic acid supplementation in women
before and during early pregnancy to help prevent congenital heart
defects in babies, just as has been recommended by Centre for
Disease Control (CDC) for preventing neural tube defects.17,18 In
1996, the United States Food and Drug Administration (FDA)
mandated that by January 1, 1998 all grain products labeled as
‘enriched’, such as breads and cereals, have folic acid added to them
to help reduce the risk of neural tube defects. Similar legislation is
needed in our Asian countries.
5. Conclusions
Thus, we conclude from this study in Asian population that
increased levels of maternal serum homocysteine are associated
with increased risk of occurrence of congenital heart defects in
their offsprings, suggesting that maternal hyperhomocysteinemia
is an independent risk factor for congenital heart defects. It would
be prudent to recommend Folic acid supplementation in women
before and during early pregnancy to help prevent congenital heartPlease cite this article in press as: Malik RA, et al. Maternal hyperho
control study in Indian population, Indian Heart J. (2016), http://dx.defects in babies, just as has been recommended by Centre for
Disease Control (CDC) for preventing neural tube defects.
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